# 89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

> **NCT03556046** · PHASE1 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Clear Cell Renal Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** 89Zr-Girentuximab

## Key facts

- **NCT ID:** NCT03556046
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-05
- **Primary completion:** 2018-12-17
- **Final completion:** 2018-12-17
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03556046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03556046, "89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03556046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*